Physician profile
Treva Vanise Risher
NPI 1720754567
$1,017.03
in general payments reported to CMS, 2019-2025
14 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.22 · 2022: $145 · 2023: $280 · 2024: $291 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $238.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $139.72 | 2021-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $139.22 | 2021-2025 | |
| Terumo Medical Corporation | $98.28 | 2024 | Glidesheath Slender |
| Kowa Pharmaceuticals America, INC. | $90.62 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Otsuka America Pharmaceutical, INC. | $79.09 | 2023-2025 | Rexulti |
| Pfizer INC. | $54.61 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $33.30 | 2025 | Zenpep |
| Organon LLC | $31.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.31 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $26.89 | 2025 | Isturisa |
| Coopersurgical, INC. | $21.39 | 2022 | |
| Novo Nordisk INC | $17.64 | 2024 | Wegovy |
| Bioventus LLC | $15.63 | 2023 | Gelsyn-3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Treva Risher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.